Cargando…

The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is the standard first-line therapy for metastatic lung adenocarcinoma harboring sensitive EGFR mutations. Tumor surface programmed death-ligand 1 (PD-L1) is expressed in some metastatic EGFR-mutated lung adenocarcinoma, but its...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Ping-Chih, Wang, Chih-Wei, Kuo, Scott Chih-Hsi, Lin, Shu-Min, Lo, Yu-Lun, Huang, Allen Chung-Cheng, Chiu, Li-Chung, Yang, Cheng-Ta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167989/
https://www.ncbi.nlm.nih.gov/pubmed/32092879
http://dx.doi.org/10.3390/biomedicines8020036
_version_ 1783523610244153344
author Hsu, Ping-Chih
Wang, Chih-Wei
Kuo, Scott Chih-Hsi
Lin, Shu-Min
Lo, Yu-Lun
Huang, Allen Chung-Cheng
Chiu, Li-Chung
Yang, Cheng-Ta
author_facet Hsu, Ping-Chih
Wang, Chih-Wei
Kuo, Scott Chih-Hsi
Lin, Shu-Min
Lo, Yu-Lun
Huang, Allen Chung-Cheng
Chiu, Li-Chung
Yang, Cheng-Ta
author_sort Hsu, Ping-Chih
collection PubMed
description Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is the standard first-line therapy for metastatic lung adenocarcinoma harboring sensitive EGFR mutations. Tumor surface programmed death-ligand 1 (PD-L1) is expressed in some metastatic EGFR-mutated lung adenocarcinoma, but its impact on the efficacy of EGFR-TKIs is unclear. We retrospectively investigated 117 untreated metastatic lung EGFR mutated adenocarcinoma patients with a PD-L1 immunohistochemistry test. The PD-L1 expression level was classified by tumor proportion scores (TPS). Forty-five patients had negative expression (TPS < 1%), 45 had a weak expression (TPS 1–49%), and 27 had a strong expression (≥50%). All patients recruited in this study received EGFR-TKIs as a first-line therapy. No significant differences were observed for objective response rates (68.9% versus 62.2% versus 73.1%, p = 0.807) and median time to treatment failure (TTF) (12.17 versus 13.17 versus 11.0 months, p = 0.443) of first-line EGFR-TKIS among the three groups of patients (negative versus weak versus strong). The median overall survival was 21.27 versus 20.63 versus 19.43 months among the three groups of patients (p = 0.77). Our results demonstrated that PD-L1 did not affect the efficacy of first-line EGFR-TKIs in metastatic EGFR mutated lung adenocarcinoma. Thus, EGFR-TKIs are suggested as the preferred clinical therapy for these patients, despite their PD-L1 levels.
format Online
Article
Text
id pubmed-7167989
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71679892020-04-21 The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma Hsu, Ping-Chih Wang, Chih-Wei Kuo, Scott Chih-Hsi Lin, Shu-Min Lo, Yu-Lun Huang, Allen Chung-Cheng Chiu, Li-Chung Yang, Cheng-Ta Biomedicines Article Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is the standard first-line therapy for metastatic lung adenocarcinoma harboring sensitive EGFR mutations. Tumor surface programmed death-ligand 1 (PD-L1) is expressed in some metastatic EGFR-mutated lung adenocarcinoma, but its impact on the efficacy of EGFR-TKIs is unclear. We retrospectively investigated 117 untreated metastatic lung EGFR mutated adenocarcinoma patients with a PD-L1 immunohistochemistry test. The PD-L1 expression level was classified by tumor proportion scores (TPS). Forty-five patients had negative expression (TPS < 1%), 45 had a weak expression (TPS 1–49%), and 27 had a strong expression (≥50%). All patients recruited in this study received EGFR-TKIs as a first-line therapy. No significant differences were observed for objective response rates (68.9% versus 62.2% versus 73.1%, p = 0.807) and median time to treatment failure (TTF) (12.17 versus 13.17 versus 11.0 months, p = 0.443) of first-line EGFR-TKIS among the three groups of patients (negative versus weak versus strong). The median overall survival was 21.27 versus 20.63 versus 19.43 months among the three groups of patients (p = 0.77). Our results demonstrated that PD-L1 did not affect the efficacy of first-line EGFR-TKIs in metastatic EGFR mutated lung adenocarcinoma. Thus, EGFR-TKIs are suggested as the preferred clinical therapy for these patients, despite their PD-L1 levels. MDPI 2020-02-19 /pmc/articles/PMC7167989/ /pubmed/32092879 http://dx.doi.org/10.3390/biomedicines8020036 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hsu, Ping-Chih
Wang, Chih-Wei
Kuo, Scott Chih-Hsi
Lin, Shu-Min
Lo, Yu-Lun
Huang, Allen Chung-Cheng
Chiu, Li-Chung
Yang, Cheng-Ta
The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
title The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
title_full The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
title_fullStr The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
title_full_unstemmed The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
title_short The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
title_sort co-expression of programmed death-ligand 1 (pd-l1) in untreated egfr-mutated metastatic lung adenocarcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167989/
https://www.ncbi.nlm.nih.gov/pubmed/32092879
http://dx.doi.org/10.3390/biomedicines8020036
work_keys_str_mv AT hsupingchih thecoexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma
AT wangchihwei thecoexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma
AT kuoscottchihhsi thecoexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma
AT linshumin thecoexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma
AT loyulun thecoexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma
AT huangallenchungcheng thecoexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma
AT chiulichung thecoexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma
AT yangchengta thecoexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma
AT hsupingchih coexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma
AT wangchihwei coexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma
AT kuoscottchihhsi coexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma
AT linshumin coexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma
AT loyulun coexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma
AT huangallenchungcheng coexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma
AT chiulichung coexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma
AT yangchengta coexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma